Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 3/20 | 0.41 |
| ▸ | MMP13 | P45452 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | GNG2 | P59768 | 1/20 | 0.39 |
| ▸ | GNB1 | P62873 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5566519 | 0.85 | CYP11B2 (0.43) | CYP11B2MMP13PIN1DYRK1AGRM2 | |
| SCHEMBL5565734 | 0.85 | PIN1 (0.48) | CYP11B2PIN1DYRK1ATERTMEN1 | |
| SCHEMBL5989830 | 0.82 | NQO2 (0.47) | NQO2KDM4EALDH1A1MEN1MMP1 | |
| SCHEMBL1315731 | 0.77 | KDM4E (0.52) | NQO2KDM4EALDH1A1MEN1ALOX15 | |
| SCHEMBL2907684 | 0.77 | HSD17B14 (0.43) | CYP11B2DYRK1AGRM2SCN9A | |
| SCHEMBL5776609 | 0.76 | PLAU (0.46) | CYP11B2KDM4EALDH1A1MEN1ALOX15 | |
| SCHEMBL5990759 | 0.75 | ALDH1A1 (0.58) | NQO2ALDH1A1MEN1ALOX15KMT2A | |
| SCHEMBL15131951 | 0.73 | NCEH1 (0.42) | CYP11B2MMP13PIN1DYRK1AKDM4E | |
| SCHEMBL6080353 | 0.73 | NQO2 (0.41) | NQO2KDM4EALDH1A1HPGDMAPT | |
| SCHEMBL16401883 | 0.72 | PLA2G2A (0.48) | CYP11B2KDM4EALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217794-B2 | Compounds and methods for treatment of thrombosis | DAIAMED, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | EXITHERA PHARMACEUTICALS LLC | 2005-06-30 | — | — | US | disclosed |
| WO-2004103270-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES LLC (US) | 2004-12-02 | — | — | WO | disclosed |
| WO-2004089297-A2 | COMPOUNDS AND METHODS FOR TREATMENT OF THROMBOSIS | SUNTORY PHARMACEUTICAL RESEARCH LABORATORIES, LLC (US) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143317-A1 | Compounds and methods for treatment of thrombosis | SERPINC1, F11, F13B | CYP11B2 2296/4885NQO2 1921/4885MMP13 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.